论文部分内容阅读
目的 探讨不同他汀类药物治疗冠心病的疗效与安全性对比.方法 将冠心病患者116例,采用数字随机法将其分为2组,甲组和乙组,每组58例,甲组患者采用瑞舒伐他汀治疗,乙组患者采用阿托伐他汀治疗,比较两组患者的临床治疗效果.结果 治疗后,两组患者的各项指标均得到了明显的改善,并且甲组患者的甘油三酯、胆固醇、低密度脂蛋白胆固醇和超敏C反应蛋白改善的程度优于乙组(P<005),两组患者的高密度脂蛋白胆固醇和血流介导的内皮舒张功能比较均无差异性(P>005);甲组和乙组发生心肌梗死,复发不良事件发生率均为86%,两组比较无差异(P>005).结论 阿托伐他汀和瑞舒伐他汀两种不同类型的他汀类药物治疗冠心病均具有较好的疗效,可以改善患者的血脂、内皮质功能,同时减轻患者的炎症,疗效相近,安全性高,值得推广.
Objective To investigate the efficacy and safety of different statins in the treatment of coronary heart disease.Methods One hundred and sixteen patients with coronary heart disease were divided into two groups according to the number randomization method, group A and group B, with 58 cases in each group. Patients in group A Rosuvastatin treatment, group B patients treated with atorvastatin, the clinical efficacy of the two groups were compared.Results After treatment, the two groups of patients were significantly improved in all indicators, and group A patients with triglyceride Estrogen, cholesterol, low-density lipoprotein cholesterol and high-sensitivity C-reactive protein were better than those in group B (P <0.05). There was no difference in high density lipoprotein cholesterol and blood flow-mediated endothelial relaxation between the two groups (P> 0.05) .Acute myocardial infarction was found in group A and group B, the incidence of recurrent adverse events were both 86%, there was no difference between the two groups (P> 0.05) .Conclusion Atorvastatin and rosuvastatin are two different Type of statin treatment of coronary heart disease have a good effect, can improve the patient’s blood lipids, endothelial function, while reducing inflammation in patients with similar efficacy, high safety, it is worth promoting.